PAM
RPRX

Panagora Asset Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Panagora Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,823
Closed -$5K – 2441
2015
Q4 		$5K Buy
+3,823
New +$12.3K ﹤0.01% 2255
2015
Q3 		– Sell
-3,663
Closed -$26K – 2592
2015
Q2 		$26K Buy
+3,663
New +$28.5K ﹤0.01% 2268
2015
Q1 		– Sell
-10,920
Closed -$109K – 2487
2014
Q4 		$109K Buy
+10,920
New +$93.1K ﹤0.01% 1843

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Panagora Asset Management's RPRX Position: Q1 2016 in Review

Panagora Asset Management sold out of Repros Therapeutics Inc. (RPRX) in Q1 2016, closing a stake of 3,823 shares — an estimated $5K sold.

Panagora Asset Management first reported a position in RPRX in Q4 2014 and held it in 3 quarters. The position peaked at $109K in Q4 2014. 53 funds tracked by Wall St. Rank hold RPRX as of Q1 2016.

  • Panagora Asset Management reported no remaining Repros Therapeutics Inc. position as of Q1 2016 after selling out during the quarter.
  • Panagora Asset Management sold 3,823 Repros Therapeutics Inc. shares in Q1 2016, an estimated $5K.
  • Panagora Asset Management first reported a position in Repros Therapeutics Inc. in Q4 2014 and held it in 3 quarters.
  • Panagora Asset Management's Repros Therapeutics Inc. position peaked at $109K in Q4 2014.
  • 53 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2016.

Based on Panagora Asset Management's 13F filing for Q1 2016, filed 16 May 2016.